Zhenge Biotech Funding: $225M Raised, Series C (2022)
Zhenge Biotech is based in Shanghai, China. It has raised $225M in total funding. Latest round: Series C.
Zhenge Biotech funding overview
Zhenge Biotech is based in Shanghai, China. Zhenge Biotech has raised $225M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in January 2022. The round record for Zhenge Biotech runs through 2022; nothing later has been disclosed. Investors on record include Goldman Sachs Asset Management, Sofina, Novo Holdings A/S, Qiming Venture Capital, IDG Capital, LYFE Capital and 2 others. 8 distinct backers are named across the disclosed rounds.
Zhenge Biotech at a glance
Total raised
$225M
Latest round
Series C
Latest round date
January 2022
Headquarters
Shanghai, China
Notable investors
Goldman Sachs Asset Management, Sofina, Novo Holdings A/S, Qiming Venture Capital, IDG Capital, LYFE Capital, Junxin Capital, Cowin Capital
Frequently asked about Zhenge Biotech funding
How much has Zhenge Biotech raised?
Zhenge Biotech has raised $225M in total disclosed funding across the rounds on record.
Who has invested in Zhenge Biotech?
Goldman Sachs Asset Management, Sofina, Novo Holdings A/S, Qiming Venture Capital, IDG Capital, LYFE Capital are named among the investors backing Zhenge Biotech.
What was the latest Zhenge Biotech funding round?
The most recent disclosed round is a Series C, announced in January 2022.
Where is Zhenge Biotech based?
Zhenge Biotech is based in Shanghai, China.
When did Zhenge Biotech last raise?
The last disclosed Zhenge Biotech round closed in January 2022 at Series C.
Totals shown for Zhenge Biotech aggregate every disclosed round on file. To see how that compares, browse the companies in Shanghai and the investors behind them below.
